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Mitochondrial acyl-coenzyme A species are emerging as important sources of protein
modification and damage. Succinyl-CoA ligase (SCL) deficiency causes a mitochondrial
encephalomyopathy of unknown pathomechanism. Here, we show that succinyl-CoA
accumulates in cells derived from patients with recessive mutations in the tricarboxylic
acid cycle (TCA) gene succinyl-CoA ligase subunit-β (SUCLA2), causing global protein hyper-
succinylation. Using mass spectrometry, we quantify nearly 1,000 protein succinylation
sites on 366 proteins from patient-derived fibroblasts and myotubes. Interestingly, hyper-
succinylated proteins are distributed across cellular compartments, and many are known
targets of the (NAD+)-dependent desuccinylase SIRT5. To test the contribution of hyper-
succinylation to disease progression, we develop a zebrafish model of the SCL deficiency and
find that SIRT5 gain-of-function reduces global protein succinylation and improves survival.
Thus, increased succinyl-CoA levels contribute to the pathology of SCL deficiency through
post-translational modifications.
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Lysine side-chains of proteins can be modified by small acylgroups, and these posttranslational modifications (PTMs)can affect protein function through various mechanisms,
including changes in structural conformation, protein activity,
protein-protein interaction, or subcellular localization1. Protein
acylation can be enzymatic; histone acetyl-transferases (HATs)
regulate gene expression by transferring the acetyl group from
acetyl-CoA to defined lysine residues on histones, thereby
opening up chromatin and allowing access to the transcriptional
machinery2. However, we first proposed that acyl-CoA metabo-
lites are highly reactive chemical species that likely modify lysine
side chains in the absence of a catalyst, particularly at the basic
pH of the mitochondrial matrix3. This prediction was validated
experimentally in vitro4–9. In fact, although protein acylation
is abundant in the mitochondria, no acyl-transferase has
been found within mitochondria, suggesting that non-enzymatic
acylation is the primary source of mitochondrial acyl-lysine
PTMs. Several acyl-groups, such as acetyl-CoA, succinyl-CoA,
propionyl-CoA, glutaryl-CoA and crotonyl-CoA, are produced in
mitochondria by catabolic metabolism4,10–12, although a large
number of acylated proteins are located in cellular compartments
other than the mitochondria6,9. Pathways involved in the gen-
eration or utilization of mitochondrial acyl-CoAs include, among
others, the tricarboxylic acid (TCA) cycle, fatty acid oxidation,
urea detoxification, ketogenesis, and initial steps of cholesterol
synthesis. Importantly, these pathways are extensively modified
by acylation and are the main targets of the mitochondrial
sirtuins SIRT3, SIRT4 and SIRT5 that function as lysine deacy-
lases (KDAC)12,13. The reciprocal interplay of reversible, non-
enzymatic acylation and removal of a subset of these PTMs by
sirtuins is believed to have co-evolved as an important regulatory
mechanism of intermediary metabolism6,12,13. Moreover, non-
physiological increases of protein acylation disrupt metabolic
pathways and are termed carbon stress6,7,11,12,14,15.
The sirtuin family member SIRT5 is located in the cytosol and
mitochondria where it removes negatively charged acylcarboxyl
moieties, including succinyl-, malonyl-, and glutaryllysine mod-
ifications16–19. The extent to which loss of SIRT5 function leads
to increased levels of protein acylation is likely determined by
substrate availability in the respective compartment. For example,
while loss of SIRT5 in mice affects both mitochondrial and
cytosolic protein malonylation, most modified proteins reside in
the cytosol where malonyl-CoA is an abundant intermediate of
triglyceride synthesis. Consequently, nearly all enzymes of the
glycolytic pathway carry malonyllysine modifications that lead to
a reduced glycolytic flux in response to loss of SIRT5 function18.
Unlike cytosolic malonylation, protein succinylation is more
prevalent in the mitochondria, where succinyl-CoA is a metabolite
of the TCA cycle that yields succinate via the enzyme succinyl-
CoA ligase (SCL)9,17. Mitochondrial protein succinylation reg-
ulates the urea cycle, ketogenesis, fatty acid oxidation and TCA
cycle flux by modulating the key enzymes of these processes16,17.
At an organismal level, whole-body knockout of Sirt5 in mice
causes cardiomyopathy in response to chronic pressure overload
and during aging, suggesting that increased succinylation causes
pathologies20,21. Increased levels of succinylation have been well
studied in conditions of SIRT5 loss-of-function, but much less is
known about how increased levels of substrates affect global
protein succinylation. Research with yeast indicates that disrupt-
ing the succinyl-CoA ligase reaction increases global protein
succinylation9. However, yeast lack enzymes with desuccinylase
activity, and it is not clear if increased succinyl-CoA levels would
overcome SIRT5-mediated desuccinylation and have functional
consequences.
SCL deficiency is a mitochondrial DNA (mtDNA) depletion
syndrome with methylmalonic aciduria (OMIM#612073 and
#245400) that manifests with a Leigh/Leigh-like encephalomyo-
pathy22–24. Altogether, more than 20 patients with mutations in the
gene encoding the α-subunit, SUCLG1, and 50 patients with
mutations of the gene encoding the ATP-specific β-subunit,
SUCLA2, have been reported. Disease-causing mutations in the
GTP-specific β-subunit, SUCLG2, have not been described. Patients
with SUCLA2 mutations typically manifest in early childhood with
a progressive encephalomyopathy, including hypotonia, dystonia,
and sensorineural deafness. The molecular characteristics include
methylmalonic aciduria and mtDNA depletion in muscle tissue, but
these are not present in all patients. Disease progression varies from
an early-onset rapidly progressive phenotype, leading to early
death before adulthood, to a slowly progressive disease22,23. The
rapidly progressing form of the disease is associated with muta-
tions that cause instability or absence of functional SUCLA2
protein or completely inactive ADP phosphorylation, whereas
mutations associated with the less fulminant disease course
commonly lead to partially impaired enzymatic function24.
Mutations in SUCLG1 cause a similar, often rapidly progressive
phenotype. Some patients also manifest with hepatopathy and
hypertrophic cardiomyopathy22,25. To date, studies of the mole-
cular pathomechanisms of SCL deficiency have focused on
the primary defect in the TCA cycle. The mechanistic basis of the
mtDNA depletion, the typically abnormal carnitine profile and the
disturbed leucine metabolism in some patients, however, remain
unknown.
In this study, we test the hypothesis that impairment of SCL
activity in patients with mitochondrial disease due to mutations
in SUCLA2 leads to increased levels of succinyl-CoA as a donor
for succinylation reactions. Indeed, we find that patient-derived
cells show increased succinyl-CoA levels that are associated
with a global increase of site-level protein succinylation. Using
mass spectrometry, we generate a detailed list of these patho-
logical succinylation targets. These proteins are involved in
many important pathways for metabolic control in mitochon-
dria, but also in the nucleo-cytosolic compartment. Many of
these pathologically succinylated proteins are regulated by
SIRT5. We therefore test whether the Sirt5 gain-of-function
modifies global protein succinylation and affects the pathology
in a novel zebrafish model of SCL disease. We find that
increased Sirt5 activity reverses the build-up of protein succi-
nylation and partially restores oxidative metabolism. In addi-
tion, survival is improved by sirt5 overexpression, an effect that
is independent of effects on mtDNA levels. In sum, we describe
global protein succinylation as a biochemical hallmark in SCL
patients, and we propose that disruption of affected pathways
by uncontrolled PTMs contributes to the complex clinical
symptoms.
Results
Succinyl-CoA ligase deficiency causes protein succinylation.
We and others reported that TCA cycle enzymes carry succiny-
lation modifications in livers from Sirt5−/− mice17,26. We applied
a comparative analysis approach to these data sets. Among all
reported succinylated proteins, TCA cycle enzymes are enriched
for succinylation modifications when all cellular proteins are
rank-sorted by the number of acylated sites corrected by the
abundance of those proteins (Wilcoxon test p-value= 6E-4,
Supplementary Fig. 1a). Most TCA cycle subunits carry several
succinylation sites (Supplementary Fig. 1b). This finding is con-
sistent with the concepts that the abundance of succinyl-CoA in
the mitochondria drives non-enzymatic acylation and that the
TCA cycle is the predominant source of succinyl-CoA4,9. In the
absence of the desuccinylase SIRT5, the abundance of many
succinylation sites on TCA cycle proteins increased (Fig. 1a).
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These data suggest that TCA cycle proteins involved in succinyl-
CoA production or utilization are uniquely susceptible to rever-
sible lysine succinylation.
From data published by Rardin et al.17, among all SIRT5-
regulated succinylation sites on the proteins in the TCA cycle,
succinylation sites on SCL subunits (SUCLG1, SUCLA2 and
SUCLG2) had the largest fold-changes (Fig. 1a and Supplemen-
tary Fig. 1c, d). Distributions of succinylation sites on TCA cycle
proteins were different from each other (log2(fold change),
ANOVA p-value = 1E-7); succinylation site changes on all three
SCL subunits (SUCLA2, SUCLG1, SUCLG2) were statistically
significantly higher than sites on the other TCA proteins FH,
IHD2, DLD, and SDHA (Tukey’s post hoc test adjusted p-value
<0.02). SUCLA2 and SUCLG2, the catalytic subunits of SCL,
each carry six succinylated lysines within their nucleotide
grasp-domains, and these residues showed SIRT5-dependent
changes up to 25-fold (Supplementary Fig. 1c, d). We mapped the
detected succinylation sites to the protein structure of SCL and
found Lys66 in SUCLG1 subunit and Lys108, Lys116 and Lys143
in the SUCLA2 subunit of SCL. These lysines are highly
conserved among species (Supplementary Fig. 1e). No variants
of Lys108, Lys116 and Lys143 of SUCLA2 were found in the Exac
database (The Exac database has been moved to gnomad: https://
gnomad.broadinstitute.org/, accessed 20.8.2018). One heterozy-
gotic allele of a synonymous nucleotide change affecting Lys66 of
SUCLG1 was found among 119,390 alleles. Lys66 locates at 3.7 Å
from bound succinyl-CoA in SUCLG1. This lysine is critical in
substrate binding as it is positioned close to the negatively
charged phosphate groups of succinyl-CoA. Succinylation of this
lysine is expected to change the local charge, resulting in
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Fig. 1 SCL deficiency causes global protein hyper-succinylation. a Quantitation of murine liver proteome succinylation shows TCA cycle enzymes are
targets of lysine succinylation in mice (C57/BL6, n= 10 wild-type, n= 10 Sirt5−/−). The SCL complex shows higher fold-changes than other TCA cycle
enzymes. “Su” in the scheme indicates a succinylation modification that is removed by SIRT5. The boxplot shows the median, the first to third quartile, the
1.5x interquartile ranges, and outliers. b Untargeted metabolomics show more succinyl-CoA and α-ketoglutarate in patient-derived fibroblasts than in
control fibroblasts. The color scale indicates fold-change. c Volcano plot of metabolite changes in fibroblasts from SCL patients and control fibroblasts.
The red dot shows succinyl-CoA. d SDS-PAGE and western blot analysis of lysine succinylation in fibroblasts cultured in standard culture conditions
(proliferative condition) and cells cultured for 5 days in low-serum conditions (non-proliferative condition). Patients (P1–P7) carry disease-causing
mutations in SUCLA2. Controls (C1–C3) are fibroblasts from age-matched patients with other mitochondrial diseases. e SDS-PAGE and western blot
analysis of lysine succinylation during myoblast differentiation in myotubes (arrow indicates stages of differentiation) of patient with SCL deficiency due to
Asp333Gly mutation in SUCLA2. Control is an age-matched patient with a non-mitochondrial disease. GAPDH was used as a loading control, and residual
SUCLA2 levels in patient samples are shown. Western blot images are representative results from 10 different independent experiments with similar
results. The p-values were calculated with Welch two-sample t-test assuming unequal variance. Source data are provided as a Source Data file. WT=wild-
type; SuK= succinyl-lysine, nd= not determined.
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decreased affinity for succinyl-CoA (Supplementary Fig. 1f, left
panel). Lys108, Lys116 and Lys143 in SUCLA2 are located on the
edge of the ADP-binding cleft. These lysine residues are
important for substrate binding by interacting with negatively
charged Glu193, Asp194 and Glu198 on the opposite side of the
ADP-binding cleft. Succinylation of these conserved lysines
changes the local positive charge to negative, likely resulting
decreased affinity for ADP (Supplementary Fig. 1f, right panel).
These data suggest that succinylation sites on SCL are important
targets of regulation by SIRT5 and that succinylation sites on SCL
may function to inhibit SCL as part of a feedback loop.
We next asked whether loss of enzymatic flux through SCL in
patients with SUCLA2 mutations caused an increase in succinyl-
CoA levels. Untargeted metabolomics was used to compare
fibroblasts from patient and control fibroblasts. The character-
istics of each patient-derived cell line are described in Table 1.
Metabolomic data showed increased abundance for TCA cycle
metabolites upstream of SCL, specifically succinyl-CoA and α-
ketoglutarate (Fig. 1b). Notably, succinyl-CoA was the most
increased metabolite in fibroblasts from patients with SCL
deficiency (Fig. 1c and Supplementary Data 1).
The hallmark of the disease, mtDNA depletion, manifests in
patient-derived fibroblasts in non-proliferating, serum-deprived
conditions27, and therefore, we studied the patient-derived cell lines
under different culture conditions. Western-blot analysis of non-
proliferative serum-deprived fibroblasts and differentiated myotubes
from patients with disease-causing mutations in SUCLA2 showed
more global protein succinylation than cells from age-matched
controls (~8-fold) and patient myoblasts (~5-fold). Proliferating
fibroblasts cultured under standard conditions showed a 1.9-fold
increase of global protein succinylation in SUCLA2-patients (Fig. 1d,
e and Supplementary Figs. 2 and 3).
Thus, high succinyl-CoA levels resulting from reduced SCL
enzymatic activity are sufficient to cause accumulation of protein
succinylation in post-mitotic cells of patients with SCL deficiency.
These data identify global protein succinylation as a biochemical
hallmark in SUCLA2 patients.
Proteomic analysis of lysine succinylation targets. To identify
and quantify specific lysine residues in proteins that are succi-
nylated when SCL flux is impaired, we used antibody-based
enrichment of succinylated peptides and mass spectrometry (MS)
as described28,29 (Fig. 2a). To account for potential changes in
protein abundance, we also separately quantified proteins and
found very few protein-level changes resulting from SCL defi-
ciency (Supplementary Data 2 for fibroblasts and Supplementary
Data 3 for myotubes). Protein quantities were used to correct site-
level changes enabling comparison of a pseudo site occupancy.
In fibroblasts, we identified 933 succinylated lysine (SuK)
residues distributed across 366 proteins (Fig. 2b, c, Supplemen-
tary Data 4). In myotubes, 194 lysine residues in 91 proteins were
succinylated; most (86%) were also detected in fibroblasts (Fig. 2b,
c, Supplementary Data 5). The majority of SuK sites were found
more often in patient samples than controls (fold change >2,
FDR < 0.05) (Fig. 2d, e). Most proteins had a single SuK site, but
several had multiple modifications (Fig. 2f). We performed gene
ontology (GO) term enrichment analyses with the list of
succinylated proteins found in fibroblasts to identify the subset
of proteins that harbor increases in lysine succinylation due to
SCL deficiency. This analysis does not reveal the true population
of modified proteins because of analytical bias toward detecting
sites on the most abundant proteins30, but it does reveal the types
of proteins we followed in our study. As expected, the TCA cycle
Gene Ontology (GO) term was significantly enriched at the top of
the list (Fig. 2g). Our data also contained overrepresentation of
succinylation sites on proteins involved in mitochondrial energy
production, such as ATP biosynthesis, pyruvate metabolism and
β-oxidation. Additionally, GO terms representing proteins out-
side the mitochondria were enriched, such as cell-cell adhesion,
protein folding, and glycolysis/gluconeogenesis. A plot of the top
20 proteins sorted by number of lysine marks (Fig. 2h) and fold-
change of individual lysine residues (Fig. 2i) showed that we
detect many succinylation sites on proteins that reside in different
subcellular compartments, including mitochondria, the cytosol
and the endoplasmic reticulum. Notably, this subset of sites
almost certainly is biased toward the more abundant proteins in
the sample and, therefore, does not reflect the true population of
sites influenced by SCL deficiency. We expected enrichment of
mitochondrial pathways due to their proximity to succinyl-CoA
production, since we observed that nearly all succinylation sites
increase and we expect this process to be nonenzymatic. Thus,
there should be no true enrichment in functional categories. Still,
Table 1 Characteristics of SCL patients and respective gene mutations.
Patient P1 P2 P3 P4 P5 P6 P7
Gender M M F M F M F
Age at
disease onset
5 mo 6 mo 2 mo 5 mo 5 mo 2 mo 12 mo
Proteomics
analysis
+ + +
Metabolomics
analysis
+ + + + + + +
Nucleotide change c.998A > G c.998A > G/13q14 deletion
(1.54Mb)
c. 534+ 1G > A c.1219C > T
Amino
acid change
Asp333Gly Asp333Gly/13q14 deletion Splice site mutation,
skipping of exon 4
Arg407Trp
OXPHOS defect Normal (muscle, histochemistry
and biochemical analysis)
Partial deficiency of CI+ CIII
(muscle, biochemical analysis)
Slight decrease of CI, CIII
and CIV (muscle, SHS
immunoblot); normal/
slight decrease of CIV
(fibroblasts, SHS
immunoblot)
Normal (muscle, histology,
EM and OXPHOS analysis)
References 24 35,59 This report
Mutations and clinical data of patients 1–6 were reported in the indicated references. Patients included in the proteomics and metabolomics analyses indicated with +. M=male, F= female, mo =
months. P= patient.
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Fig. 2 Proteomics analysis of protein lysine succinylation. a Workflow for label-free proteomics quantitation of succinyl-lysine residues in whole-cell
lysates of fibroblasts and myotubes from SCL patients and controls. Samples were trypsin-digested. Succinylated lysines were enriched by immune affinity
and analyzed by mass spectrometry (n= 2 control, n= 3 SCL patient-derived fibroblasts; n= 2 control, n= 1 patient-derived myotubes; A technical
replicate of patient-derived myotube samples was used). b Venn diagram of total number of succinylated lysine sites identified in fibroblasts and myotubes.
c Venn diagram of total number of proteins carrying succinyl-lysine sites. d Boxplot of fold-changes of succinyl-lysine mean intensities in fibroblasts and
myotubes from patients compared to controls. Orange points indicate lysine marks enriched significantly more in patient samples, compared to controls.
The boxplot shows the median, the first to third quartile, the 1.5x interquartile ranges, and outliers. e Table of identified SuK sites in fibroblasts and
myotubes showing total numbers of SuK sites, numbers of SuK sites significantly enriched in SCL patient samples, and the median values of log2-
transformed ratios of patient-derived samples, compared to that from control cells. f Distribution of frequencies of succinylated lysine PTMs per detected
protein. More than half of the proteins contain only one succinylated lysine. Oher proteins carry more than one SuK mark with a maximum of 27 SuK PTMs.
g GO biological process term enrichment analysis of hyper-succinylated proteins from the fibroblast samples. Statistical significance was determined using
fisher exact test. h Barplot of the 20 proteins with the highest numbers of SuK marks identified in our analysis. Highly succinylated proteins are found in
different cellular compartments, including mitochondria, the nucleus, the endoplasmic reticulum and the cytosol. Protein ratio indicates levels of proteins in
SCL patient-derived cells vs control cells. i Barplot of the 20 most dynamically affected succinylation marks in the absence of SUCLA2 as detected in this
analysis. Source data are provided as a Source Data file. SuK= succinyl-lysine; TCA= tricarboxylic acid; BCAA= branched chain amino acid.
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these analyses are presented to convey the analytical coverage of
our study. In summary, SCL deficiency leads to high levels of
reactive succinyl-CoA, which affects proteins of diverse cellular
pathways by non-enzymatic lysine succinylation.
Succinylation targets overlap in SCL and Sirt5 deficiencies. The
protein with the most succinylation sites, hydroxyacyl-CoA dehy-
drogenase trifunctional multi-enzyme subunit-α (HADHA), is an
integral part of the enzyme complex that regulates β-oxidation and
a major target of SIRT3 and SIRT5 (refs. 17,21,31). Similarly, other
proteins with high numbers of succinylation sites (e.g., filamin A
(FLNA), myosin heavy chain 9 (MYH9), heat shock protein family
D 1 (HSPD1) and AFG3-like protein 2 precursor (AFG3L2)) were
found in proteomics analyses of SIRT5 deficiency26. However, these
latter studies used tissues from different species and with different
proteomics workflows. To assess a potential overlap between these
two drivers of protein succinylation, hyper-succinylated proteins
and sites detected in fibroblasts from patients with SCL deficiency
were compared with those in SIRT5 knockout (KO) mouse
embryonic fibroblasts by Park et al.26; 102 proteins carry at least
one succinylated lysine in both conditions, representing 41% of all
proteins detected with hypersuccinylation due to SCL deficiency,
or 29% of hyper-succinylated proteins detected due to deletion
of SIRT5 (Fig. 3a). Since the two studies were carried out in different
organisms and mouse protein sequences carry amino acid
insertions and deletions relative to human proteins, pairwise
sequence alignment of these 102 common proteins was performed
to allow site-level comparison. This analysis revealed that 238 sites
were in common between the two studies (Fig. 3b, Supplementary
Fig. 4, and Supplementary Data 6). Interestingly, the extent of
hyper-succinylation due to SCL deficiency was greater than what
was observed from mouse embryonic fibroblasts lacking SIRT5
(Fig. 3c).
The sites and proteins we detected are biased toward the most
abundant succinylated sites and proteins. However, another useful
way to examine the overlap between studies of SCL deficiency and
SIRT5 KO is to compare the number of modifications detected
per protein. Among these common proteins, the numbers of
succinylation sites per protein were correlated between both
conditions (r2= 0.54, p-value= 2.2e-16), including filamin A,
MYH9, HADHA and vimentin, which were some of the proteins
with the highest numbers of succinylation sites in both conditions
(Fig. 3d). Because nearly all (98%) of sites increased in levels of
succinylation due to SCL deficiency, as would be expected in a
non-enzymatic process, the sites we detected in our study likely
overlap with those in other data sets related to hyper-succinylation.
Therefore, examination of the exact fold-changes resulting from
each process on individual lysine sites in both data sets are of
interest. To this end, we aligned the amino acid sequences of all
identified proteins, taking into account amino acid insertions and
deletions that occurred during evolution, and determined those
lysines that are modified in both species. Although the comparison
of the two different species and methodologies only allows an
approximation of fold-changes, we estimate that the median fold-
changes across the differential succinylation of most of the top 11
proteins were higher in SCL deficiency than in SIRT5 deficiency
(Fig. 3e). Comparing the exact sites of these same 11 proteins
under the two conditions, we estimated that almost all sites had
lower fold-changes in SIRT5 deficiency than SCL deficiency
(Supplementary Fig. 4). Notably, some proteins had sites with a
similar regulation in the two studies (e.g., Citrate Synthase and
HADHA) (Supplementary Fig. 4, Supplementary Data 6). These
data show an extensive analytical overlap between proteins
detected to accumulate SuK marks in response to SUCLA2 and
SIRT5 deficiencies, which cause increased protein succinylation
by increasing succinyl-CoA levels or decreasing lysine de-
succinylation activity, respectively.
Sirt5 modifies succinylation levels in sucla2−/− zebrafish. The
substantial overlap of pathological succinylation with SIRT5-
regulated proteins raises a question: Is pathological succinylation
modulated by SIRT5 function? Importantly, increased SIRT5
activity could be applied to reverse global protein hyper-
succinylation and could possibly restore the function of those
proteins negatively affected by pathological succinylation. To test
this hypothesis in a zebrafish model of SCL deficiency, we per-
formed targeted disruptions of sucla2, the zebrafish orthologue of
SUCLA2, and sirt5, the zebrafish orthologue of SIRT5, with
CRISPR/Cas9 genome editing. The vertebrate model zebrafish is
amenable to genetic manipulations and the study of energy
metabolism, and, important to this study, expresses all seven
sirtuin genes32,33. In zebrafish, like in mammals, SCL is a het-
erodimeric complex of three subunits: the non-catalytic subunit
suclg1 that dimerizes with suclg2, mainly in the liver and kidney,
or with sucla2 in most other organs, including the brain and the
skeletal muscle34. We selected two lines carrying out-of-
frame mutations for sucla2 and sirt5 in the germline (Fig. 4a
and Supplementary Fig. 5). In addition, we generated a gain-of-
function model overexpressing the cDNA of sirt5 ubiquitously
across tissues, Tg(ubi:sirt5;cryaa:zsgreen1) (hereafter termed Tg
(ubi:sirt5)) (Fig. 4a). qPCR analyses of sucla2 and sirt5 gene
expression confirmed that mRNA was depleted as a result of out-
of-frame mutations, leading to nonsense-mediated decay (Fig. 4b,
c). qPCR analysis of the sirt5 transgene expression showed an
approximately 7-fold overexpression relative to the level of
endogenous sirt5 mRNA (Fig. 4d).
Using these models, we found that baseline protein succinyla-
tion was not detected in sirt5mutant zebrafish in the larval stages,
which are characterized by proliferation and cell growth. This is
similar to what was observed in Sirt5 loss-of-function cell lines in
proliferative conditions17 (Fig. 4e). By contrast, loss of sucla2
resulted in an increased succinylation pattern at 7 days post
fertilization (dpf) (Fig. 4e). Combined deficiency of sirt5 and
sucla2 further increased global protein succinylation significantly,
suggesting that succinylation is determined in vivo by both levels
of free succinyl-CoA and Sirt5 de-succinylase activity (Fig. 4e).
Overexpression of the sirt5 transgene using Tg(ubi:sirt5) zebrafish
in the backgrounds of wild-type or sucla2−/− genotypes only
partially reversed protein succinylation, suggesting that not all
sites affected by pathological succinylation can be efficiently de-
succinylated by Sirt5 (Fig. 4f).
In contrast to sucla2−/− larvae, heterozygous carriers of sucla2
mutant alleles survive into adulthood. To further investigate the
occurrence of global protein succinylation in SCL deficiency, we
quantified succinylation levels in skeletal muscle of sucla2+/− ani-
mals. Surprisingly, even heterozygosity of sucla2 mutations led to
accumulation of protein succinylation in adult tissues that was
amplified by sirt5 deficiency (Supplementary Fig. 6a). In a second
set of experiments, we generated transgenic zebrafish that
specifically overexpress sirt5 in skeletal muscle and crossed this
line into the sucla2+/− background. Overexpression of sirt5 led to a
significant reduction of protein succinylation levels (Supplementary
Fig. 6b). In summary, our data show that sirt5 is a modifier gene of
protein succinylation in SCL deficiency.
Sirt5 gain of function improves survival. Genetic disruption of
sirt5 impairs several metabolic pathways, including fatty acid
oxidation17,21,26. Our analysis also indicates that proteins related
to oxidative metabolism and TCA cycle function are affected by
succinylation in SCL deficiency. We, therefore, determined
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oxygen consumption rate (OCR) of whole zebrafish larvae, using
a seahorse analyzer to measure changes in oxidative metabolism.
As expected, sucla2 deficiency led to a strong reduction of basal
and maximal, uncoupled respiration (Fig. 5a–c). Whereas over-
expression of sirt5 in wild-type animals did not lead to a sig-
nificant change in OCR, Sirt5 significantly increased the OCR in
sucla2 mutant zebrafish (p= 0.0067) and showed a trend towards
increased basal respiration (p= 0.0725) (Fig. 5a–c). Next, we
determined if this improvement in oxidative metabolism was
associated with changes in mtDNA content. We found that,
indeed, sucla2 deficiency led to a significant mtDNA depletion,
recapitulating this hallmark of SCL disease (Fig. 5d). Exogenous
overexpression of sirt5 did not affect mtDNA content, compared
to the mutant background alone, indicating that changes in
oxygen consumption rate are not linked to correction of mtDNA
levels (Fig. 5d). Improvement in respiration was also independent
of a potential normalization of metabolite levels directly upstream
of SCL, including succinyl-CoA and α-ketoglutarate, but instead
moderately increased the levels of α-ketoglutarate (Supplemen-
tary Fig. 7a–d). These data suggest that increasing Sirt5 activity
cannot directly overcome reduced substrate flux through SCL
but has a profound impact on mitochondrial respiratory capacity
in SCL deficiency.
Finally, we aimed to determine if sirt5 affects the health of
sucla2-deficient zebrafish. In agreement with the strongly reduced
capability for oxidative metabolism, sucla2−/− larvae die prema-
turely starting at 10 dpf and do not reach adulthood (Fig. 5e). By
contrast, sucla2−/− zebrafish mutants that were raised on the
transgenic background of sirt5 overexpression showed signifi-
cantly improved median survival, indicating that reducing the
load of protein succinylation had benefited the health of the
larvae (Fig. 5e). Since sucla2 mutant animals show a reduced
oxygen consumption rate and mitochondrial dysfunction com-
monly leads to a shift to anaerobic glycolytic metabolism, we also
analyzed the survival of sucla2 mutant and control animals in
volume-restricted medium. In this set-up, zebrafish larvae were
kept in 96-well plates at a defined volume of 200 μL where the
metabolism of the animals leads to progressive acidification of the
surrounding medium. We found that sucla2−/− animals died
significantly earlier than wild-type controls. Transgenic over-
expression of sirt5, by contrast, showed a trend to an improved
median survival (p= 0.146) (Supplementary Fig. 7e).
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We showed that protein succinylation in response to reduced
SCL flux impacts on cellular function and pathological progres-
sion in vivo and that a targeted reduction of succinylation levels is
a promising strategy to improve oxidative metabolism and health
in SCL deficiency.
Discussion
Mutations in SUCLA2 or SUCLG1 cause an incurable, progressive
childhood-onset mitochondrial disease characterized by a pro-
gressive encephalomyopathy22,35. We used an untargeted
approach to examine the metabolic consequences of SCL defi-
ciency in patients and uncovered a potential PTM-linked disease
mechanism. Our results show that SCL deficiency and the
reduced flux through SCL lead to succinyl-CoA accumulation and
widespread lysine succinylation of proteins in mitochondria and
other cellular compartments. This finding is relevant because
increased protein acylation is commonly associated with loss-of-
function and changes in metabolic network regulation6,11,36. The
interactions of diet as source of acyl-CoA species with the gen-
otype could lead to a variable degree of protein acylation and
protein network dysfunction, and explain, at least partially, the
heterogeneity in onset and severity of symptoms. Our proteomics
approach identified almost 1,000 lysine residues, of which 899 are
statistically increased in cell lines of patients with disease-causing
SUCLA2 mutations. These data suggest that, while baseline levels
of succinylation are low, an increase of succinyl-CoA in mito-
chondria is sufficient to overcome the capacity of SIRT5 to effi-
ciently remove succinylation marks.
The majority of succinylated proteins we identified are located
within the mitochondria and affect bioenergetic pathways,
including the TCA cycle, ATP-synthesis, and β-oxidation. Less
expected was the observation of hyper-succinylation of proteins
in pathways outside mitochondria, a phenomenon that has been
described in other studies9,26,30; proteins responsible for cell-cell
adhesion, branched-chain amino acid catabolism and glycolysis
were also enriched for succinyl-lysine marks. In SCL deficiency,
ed
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the driver of succinylation is the intra-mitochondrial built-up of
succinyl-CoA due to mutations in SUCLA2 and, therefore,
reduced enzymatic flux. Because succinyl-CoA is a negatively
charged molecule and should not cross the mitochondrial
membrane, the mechanism of lysine hyper-succinylation outside
the mitochondria is not clear. Although pathways for transfers of
acyl-groups across the mitochondrial membrane are known for
other acyl-CoA moieties, no such mechanism has been reported
for succinyl-CoA37,38. Cytosolic succinylation in this and other
contexts could be caused by leakage of succinyl-CoA through
damaged mitochondrial membranes, an unidentified transport
mechanism for activated succinyl groups such as succinyl-carni-
tine, and secondary SIRT5 deficiency due to depletion of NAD+
levels, the latter of which has been described in other forms of
mitochondrial dysfunction or disease13,39,40.
The greater average change of succinylation in response to
loss of SUCLA2, compared to loss of SIRT5, was hinted at by the
cross-species/cross-method comparison and substantiated in the
direct comparison of loss-of-function genotypes in zebrafish.
These observations suggest that the increase is substantial.
Because these modifications converge on the same target pro-
teins, these changes may cause pathological events that resemble
those reported in Sirt5−/− mice21. For example, HADHA, a
subunit of the trifunctional protein complex, was a major target
with 27 detected lysine sites. Accumulation of succinylated
HADHA could lead progressively to reduced β-oxidation, built-
up of acyl-carnitines, and ultimately contribute to cardiomyo-
pathy, a pathology that has been reported in cases of SUCLG1
deficiency. Identification of the target proteins is biased towards
those of high abundance30. Nevertheless, the pathways con-
sistently affected across studies represent important metabolic
nodes for cellular energy metabolism and are likely to be
functionally relevant.
Another important target that we identified was SHMT2, which
was among the proteins with the highest numbers of succinyl-
lysine sites. SHMT2 is a vitamin B6-dependent mitochondrial
enzyme that fluxes serine into the one-carbon pool to derive
glycine and methylenetetrahydrofolate. SHMT2 is involved in the
synthesis of purines and controls mitochondrial translation
initiation, linking SHMT2 activity with mtDNA maintenance
and respiratory function41,42. Succinylation may, therefore,
affect SHMT2’s function by different mechanisms. Degradation of
SHMT2 by targeted ubiquitination is mediated by acetylation of
lysine 95 (ref. 43). Furthermore, hyper-succinylation on lysine 280
reduces the enzymatic activity of SHMT2 (ref. 44), although K95
and K280 were not among the eight succinyl-lysine sites found in
our data set. However, our data show that, at least in the condi-
tions studied here, the effects of SIRT5 on mitochondrial
respiration are independent of changes in mtDNA content.
To test the functional impact of SIRT5 activation, we con-
ducted a series of loss- and gain-of-function experiments in
zebrafish as an experimental model that mimics the human dis-
ease. First, we showed that this zebrafish model recapitulates the
phenotype of protein hyper-succinylation in the cells from SCL
patients. The increase of protein succinylation in zebrafish
appeared to be larger in response to sucla2 deficiency than with
loss of sirt5, confirming what was predicted by comparing data
from patient-derived fibroblasts and Sirt5−/− mouse embryonic
fibroblasts. Additional loss of sirt5 further increased protein
succinylation, and overexpression of sirt5 could partially rescue
elevated lysine succinylation, arguing that increases of succinyl-
CoA override intrinsic SIRT5 activity in a dose-dependent
manner. Interestingly, even zebrafish heterozygous for sucla2
mutations accumulated succinylated proteins in skeletal muscle,
an effect that was further increased in the background of sirt5
loss-of-function. This finding is of interest as it suggests that
protein succinylation occurs in recessive carriers of the disease,
such as the children’s parents, and that it may reduce mito-
chondrial energy metabolism with age or in other conditions
associated with NAD+ depletion. Consistent with the concept
that sirt5 is a disease modifier of SCL deficiency, zebrafish mutant
larvae with extra copies of sirt5 showed improved survival. We
found that sucla2−/− mutant zebrafish died prematurely starting
at 10 dpf. By contrast, overexpression of a sirt5 transgene sig-
nificantly increased survival. Of note, mtDNA levels were not
rescued by increased Sirt5 protein levels, suggesting that mtDNA
depletion is caused by mechanisms other than pathological suc-
cinylation. Metabolites directly upstream of SCL, including
succinyl-CoA and α-ketoglutarate, were also higher than in wild-
type animals suggesting that Sirt5 activation does not improve
flux through SCL. The improved survival could be due to dif-
ferent effects of Sirt5 that mitigate the consequences of TCA cycle
dysfunction in sucla2 mutant zebrafish. These mechanisms could
include in principle effects on any of the pathways identified in
this study inside and outside the mitochondria, and desucciny-
lation activity of Sirt5 is likely to have a compound effect.
Nevertheless, the partial restoration of oxygen consumption in
zebrafish larvae overexpressing sirt5 indicate that a rewiring from
glycolytic to oxidative metabolism is at least in part responsible
for the improvement in larval health. Future studies are war-
ranted to dissect which energy fuels in particular allow a
restoration of oxidative metabolism when the succinylation load
is lowered in SCL deficiency.
Notably, although we identified succinylation as a modifier of
SCL disease, the underlying genetic defect within the TCA cycle is
likely the dominant pathomechanism responsible for the severity
of the clinical symptoms. The concept of carbon stress acting on
top of the genetic defect may explain the occurrence of clinical
symptoms at a young age in patients in contrast to the age-related
phenotypes observed in Sirt5 knockout mice21.
In sum, we found hundreds of proteins that are affected by
protein succinylation in patients suffering from SCL deficiency.
We provided evidence that pathological succinylation contributes
to the disease pathology and may explain the heterogeneity of
clinical symptoms in SCL deficiency. Looking forward, this study
warrants exploration of strategies to increase sirtuin activity to
slow SCL disease progression. These may include treatment with
NAD+ precursors, such as vitamin B3-forms (niacin, nicotina-
mide riboside, nicotinamide mononucleotide). Nicotinamide
riboside remarkably improved disease signs in a mouse model of
adult-onset mitochondrial myopathy due to mutations in the
mitochondrial replicative helicase Twinkle39, and adults with the
same disease benefited from high-dose niacin40. Whether such
“metabolic modifier” interventions and/or specialized diets that
decrease the carbon load from succinyl-CoA, would benefit
SUCLA2-patients, remains to be studied.
We show that pathological succinylation acts as a disease
modifier independent of changes in mtDNA copy number and
levels of TCA cycle metabolites. This finding suggests a possible
multi-target approach of addressing the primary SCL defect and
activating SIRT5 activity, for example, through membrane-
permeable succinate to bypass the failure of producing succi-
nate in the TCA cycle45. Beyond the relevance for SCL deficiency,
our study provides evidence that non-physiological increases in
reactive carbon species contribute to cellular dysfunction and
disease through PTMs.
Methods
Protocol approvals, registrations, and patient consents. All patients diagnosed
with disease-causing mutations in SUCLA2 admitted to the participating clinics,
and from whom appropriate samples were available, were included in the study
(N= 7). All patient samples were taken and used for research with informed
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consent from the parents taken by the participating clinical institutes. All samples
were taken for diagnostic purposes, and samples from age-matched pediatric
patients with other mitochondrial diseases were used as controls, as samples from
healthy children are not available. The study was approved by the Ethics Com-
mittee for Paediatrics, Adolescents and Psychiatry of Helsinki University Hospital
and by the participating clinical institutes. Use of the samples is restricted to the
research entities listed in the protocol. Fibroblasts were available from all patients
(P1–P7), and myoblasts from one patient (P1). Metabolomics was performed on all
fibroblast lines, and proteomics on fibroblasts from one patient with each of the
disease-causing mutations (n= 3), and the myoblast line (n= 1).
Cell culture and lysate preparation. Fibroblasts from control patients and patients
with mutations in SUCLA2, immortalized by retroviral transduction of E6/E7
proteins of human papilloma virus, were grown to 80% confluence and then cul-
tured in 0.5% serum for 5 days. Cells (3.5–4.8 × 107) in active growth phase were
harvested by scraping for metabolomics analysis and trypsin for sodium dodecyl
sulfate-polyacryylamide gel electrophoresis (SDS-PAGE) and proteomics (~3mg of
soluble protein per sample), washed and frozen as pellets. Similarly, myoblasts from
two control individuals and one SUCLA2-deficient patient were differentiated into
myotubes before collection of myoblasts and myotubes. Metabolomics analyses were
performed on all fibroblast lines of the seven patients and three control subjects.
Proteomics were performed using three cell lines from patient-derived
fibroblasts and from two control patients. Proteomics experiments on myotubes
were performed using one patient-derived myoblast cell line and two patient-
derived myoblast cells lines. To enable analysis of proteomics data of the myotubes,
we compared two technical replicates of the patient line to two control myotube
samples. Two pellets were collected from individual cultures of each cell line.
Antibodies and reagents. A table with antibodies and reagents used in this study
is available in Supplementary Table 1.
Sample preparation for proteomic experiments. Frozen cell pellets from control
and patient-derived fibroblasts and myotubes were thawed in lysis buffer (8 M urea,
50 mM Tris, pH 7.5, 1x HALT protease inhibitor cocktail, 150 mM NaCl, 5 μM
trichostatin A, and 5 mM nicotinamide) and sonicated on ice with three bursts for
10 s with a probe-tip sonicator. Lysates were clarified by spinning at 20,000g for
15 min at room temperature, and the soluble protein was moved to a new tube.
Protein concentrations were determined using the BCA assay. Protein disulfides
were reduced by adding DTT to a final concentration of 4.5 mM for 30 min at
37 °C, and free thiols were capped after cooling to room temperature by adding
10 mM iodoacetamide and incubating proteins for 30 min in the dark. Samples
were diluted fourfold with 50 mM Tris buffer, pH 7.5, and proteins were enzy-
matically hydrolyzed overnight by adding trypsin at a ratio of 1:50 (wt:wt) trypsin
to substrate. The enzymatic hydrolysis was then quenched by the addition of
formic acid to 1% final concentration by volume, and the solution was clarified by
centrifugation at 2000g for 10 min at room temperature. The supernatant con-
taining tryptic peptides was desalted using Oasis HLB vacuum cartridges (Waters).
A small aliquot of the desalted peptide elution from each column containing
approximately 20 µg was separated from the major portion of the peptides to be
used for separate analysis of any protein-level changes. Desalted peptides were
dried completely using a vacuum centrifuge. Dried peptide powder was then
resuspended in IAP buffer (50 mM MOPS, 10 mM phosphate, 50 mM NaCl, pH
7.2) by pipetting, and succinylated peptides were enriched using anti-succinyl
lysine antibody conjugated to agarose beads (Cell Signaling Technologies,
PTMScan # 13764), according to the manufacturer’s instructions except that 10 μL
of beads were used for each sample (1/4 of a single tube containing 40 μL of beads).
Succinylated peptides eluted from the antibody-bead conjugates in 0.1% tri-
fluoroacetic acid in water were directly desalted using homemade StageTips46.
Desalted peptides were dried completely by vacuum centrifuge and stored at
−80 °C until they were resuspended in 0.2% formic acid in water for nanoflow
liquid chromatography-tandem mass spectrometry (nLC-MS/MS) analysis.
Proteomic data collection with nLC-MS/MS and data analysis. All MS data
were collected using an Eksigent nLC system with a cHiPLC column system
coupled to a SCIEX TripleTOF 6600 MS or TripleTOF 5600 system using Sciex
Analyst software version 1.7.
Peptides were analyzed by nLC-MS/MS based on the following established
workflow28,29,47: A detailed description of the workflow is provided in the
Supplementary Methods. Briefly, non-enriched peptides from the protein lysate were
analyzed by data-independent acquisition to quantify proteome changes. The
enriched fraction of succinylated peptides was analyzed twice: once by data-
dependent acquisition to yield qualitative data and a second time with data-
independent acquisition to produce quantitative data. All chromatographic and mass
spectrometric scan parameters are detailed in the Supplementary Methods.
Proteome data from non-enriched peptides was quantified using Spectronaut48 and
the pan-human spectral library (Spectronaut pulsar Version 11.0.15038.12.33511)49.
Succinylated peptides were identified and quantified using a modification of the
PIQED workflow, an automated analyses of post-translational modifications and
protein quantification based on data-independent acquisition29: First, succinylated
peptides were identified by searching a database by data-dependent acquisition
against the human proteome using MaxQuant50 with the default settings except that
variable succinylation of lysine was allowed. Next, the adapted PIQED analysis
started from a spectral library of succinylated peptides built from MaxQuant
identifications, which were quantified in Skyline51. Relative quantities of proteins
were used to correct changes in observed PTM abundance before statistical
comparison of quantities between patient samples and controls with mapDIA52.
Changes to succinylation sites were considered significant when the log2 change was
>1 at Q < 0.05 when different conditions compared to each other. For direct
comparison of succinyl-lysine sites in mice (from Park et al.26) and human (our
study), pairwise sequence alignments were performed to identify those sites that
show succinylation in both sequences.
Gene ontology term enrichment analysis. Compared to controls, 353 proteins
were hyper-succinylated in patient samples were from fibroblast data and were
used as input for GO term enrichment analysis with DAVID53. Enriched terms are
from the GOTERM_BP_DIRECT group; and the p-value used is from the fisher
exact test.
Identification and quantification of metabolites. Intracellular metabolites from
cells were harvested following standard protocols using 80% methanol/water as
solvent54–56, and dry pellets were stored in −80 °C freezer until ready for LC-MS
analysis. For acyl-CoA analysis, dry pellets were reconstituted into 30 μL of sample
solvent (water containing 50 mM ammonium acetate), and 10 μL was injected into
the LC-MS. For non-acyl-CoA polar metabolite analysis, pellets were reconstituted
into 30 μL of sample solvent (water:methanol:acetonitrile, 2:1:1, v/v/v), and 3 μL
was injected into the LC-MS.
Mi 3000 UHPLC (Dionex) was used for metabolite separation. For polar
metabolite analysis, a hydrophilic interaction chromatography method (HILIC)
with an Xbridge amide column (100 × 2.1 mm i.d., 3.5 μm; Waters) was used, and
detailed parameter settings were according to standard protocols57. For acyl-CoA
analysis, a reversed phase liquid chromatography method employing a Luna C18
column (100 × 2.0 mm i.d., 3 μm; Phenomenex) was used54. LC was coupled with
Q Exactive Plus mass spectrometer (Thermo Scientific) for metabolite separation
and subsequent detection. The Q Exactive Plus mass spectrometer was equipped
with a HESI probe, and for non- acyl-CoA polar metabolite analysis, it was
operated in the full-scan mode with positive/negative switching with the resolution
set at 70 000 (at m/z 200). When it was used for acyl-CoA analysis, it was operated
in the positive ion mode with a full-scan range of 150–1000 (m/z). LC-MS data
were analyzed using Sieve 2.0 (Thermo Scientific), and the integrated area under
metabolite peak was used to compare the relative abundance of each metabolite in
different samples in the same batch. Retention times for each metabolite are
included in Supplementary Data 1 and can also be found in methods papers
outlining the experimental procedures applied in this study54–56.
Intracellular metabolites from zebrafish were harvested from pools of eight
larvae that were snap-frozen in liquid nitrogen and kept at −80 °C before analysis.
A cold biphasic extraction was employed58. In short, tissues were homogenized in
300 µL of −20 °C methanol/water (5:3) using 5-mm stainless steel beads in a tissue
grinder (Qiagen TissueLyser II) for 1:50 min:sec at 20 Hz. A fully labeled 13C yeast
biomass (50 μL) were added to the homogenate as internal standard. Further,
500 µL of methanol/water (5/3, v/v) (−20 °C) and 500 µL of chloroform (−20 °C)
were added; the samples were agitated for 10 minutes at 4 °C in a thermo-shaker
(Thermomixer C, Eppendorf), followed by 10 minutes of centrifugation. After
extraction, the upper polar phase was recovered. The recovered extract was dried
overnight in a vacuum centrifuge at 4 °C and 5 mbar, and then stored at −80 °C,
before analysis. Dried samples were reconstituted in 20 µL of 60% (v/v)
acetonitrile/water, and the supernatants transferred into glass vials for LC-MS
analysis. Five microliters were injected into a Vanquish UHPLC (Thermo
Scientific), equipped with a hydrophilic liquid chromatography column (ZIC-
pHILIC column, 100 ×2.1 mm, 5 µm, with a ZIC-philic guard column 20 × 2.1 mm,
5 µm, both from Merck Sequant). Separation was achieved by applying a linear
solvent gradient in decreasing organic solvent (90–25%, 15.5 minutes) at 0.2 mL/
min flow rate and 35 °C. Aqueous 10 mM ammonium acetate with 0.04% (v/v)
ammonium hydroxide (A) and acetonitrile (B) were used as mobile phases. The
eluting metabolites were analyzed on an Orbitrap Fusion Lumos mass spectrometer
(Thermo Scientific) with a heated electrospray ionization (H-ESI) source. The mass
of the metabolites was assessed with on-the-fly positive and negative mode
switching at a resolution of 60,000 at an m/z of 200. The spray voltages were 3500
V and 3000 V for positive and negative modes, respectively. The sheath gas was
20 AU, and the auxiliary gas was kept 15 AU. The temperature of vaporizer was
280 °C, and the temperature of the ion transfer tube was 310 °C. Instrument control
and peak integration were conducted with the Xcalibur 4.2.47 software (Thermo
Scientific). Metabolites were identified according to their exact mass, and the signal
intensities were normalized to a 13C internal standard.
SDS-PAGE and immunoblotting. Total cellular protein was extracted from patient
and control fibroblasts and myoblasts. Protein extracts (5 µg) were separated on
12% SDS-PAGE (CriterionTM TGX Stain-Free, Biorad, Hercules, CA, Cat. #567-
8045). Western blots for protein succinylation were performed by standard
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method17. Uncropped western blot images are shown in Supplementary Figs. 2, 3
and 8. Antibodies as well as working dilution are specified in Supplementary
Table 1.
Protein structure modeling. Structural modeling was performed using SWISS-
Model Server and multiple sequence alignment using PROMALS3D Server. Model
and Figure preparations were done with Discovery Studio v4.1 (Accelrys) as
reported24.
Zebrafish husbandry and generation of zebrafish lines. Adult zebrafish of the
commonly used AB line were raised at 28 °C under standard husbandry conditions.
All experimental procedures were carried out according to the Swiss and EU ethical
guidelines and were approved by the animal experimentation ethical committee of
Canton of Vaud (permits VD-H13 and VD3177). Transgenic zebrafish were
generated using I-SCEI meganuclease-mediated insertion into AB embryos at the
one-cell stage of a construct harboring the zebrafish sirt5 under the control of the
skeletal muscle-specific actc1b promoter or the ubiquitous ubi promoter. For rapid
selection of transgenic animals, the injected constructs carried an eye-marker
cassette harboring ZsGreen under the control of the cryaa (alpha-crystallin A
chain) promoter in reverse direction. Transgenic carriers were outcrossed with AB
fish to raise transgenic and wild-type siblings. The novel transgenic lines were
registered at the central repository ZFIN.org under the designation Tg(ubi:sirt5;
cryaa:zsgreen1)nei005 and Tg(actc1b:sirt5;cryaa:zsgreen1)nei006. The transgenic lines
can be found on www.zfin.org in the section “Tg/Mutants” entering the identifier
(e.g. nei005) in the search field.
Gene disruptions of the sirt5 and sucla2 loci in zebrafish were generated using
CRISPR/Cas9 genome editing. In brief, zebrafish embryos were injected at the one-
cell stage with recombinant CAS9 protein and single guide RNAs targeting exon 3
of sucla2 and exon 5 of sirt5. Primers were designed to amplify a short amplicon
flanking the targeted sites, and high-resolution melt (HRM) analysis was
performed on genomic DNA of the injected embryos to confirm successful gene
disruption using a SYBR PCR mix on a LightCycler (Roche Life Science). Primer
pair sequences were used as follows: sucla2: 5′- CTTGGTTATAAAAGCCCAAG
TGC-3′ (forward) and 5′-GAGTAAACGATTCTGACTCCTCC-3′ (reverse); sirt5:
5′-GGGTGGGTAATTGGGAAGTT-3′ (forward) and 5′- GATGGTCCAGTCCT
GGTTTG-3′ (reverse). Adult F0 zebrafish were outcrossed to wild-type AB animals
to generate a F1 generation. HRM analysis on genomic DNA from tails of
zebrafish adults was used to identify founder animals, and the out-of-frame
mutations were confirmed using gene sequencing. The zebrafish mutant
lines were registered at the central repository ZFIN.org with the designations
sucla2−/−nei010 and sirt5−/−nei004. The mutant lines can be found on www.zfin.
org in the section “Tg/Mutants” entering the identifier (e.g., nei004) in the
search field.
Gene expression and mtDNA quantification. For gene expression analysis, flash
frozen pooled larvae or adult muscle were lysed in Qiazol with the FastPrep®-24
tissue homogenizer (MP-Biomedials). Total mRNA was extracted using the QIA-
cube plateform and mRNAeasy kit (Qiagen). For RT-qPCR, cDNA was synthesized
using standard cDNA synthesis kit, following the manufacturer’s instructions
(Thermo Fisher). qPCR was performed with the Roche Light Cycler 480 using
SYBR green kit (Maxima SYBR Green, Thermo Fisher) and the following primers:
βactin-Fwd: GTGGTCTCGTGGATACCGCAA, βactin-Rev: CTATGAGCTGCCT
GACGGTCA, sirt5-Fwd: GGGAGTTTTACCATTACAGGCG, sirt5-Rev: ACATG
TTTAGACCCAGCCCG, sucla2-Fwd: CCGCTGGACTGAGGAATTCC, sucla2-
Rev: TCATGCAGGGAGAGCTTTCT
For mtDNA quantification, genomic DNA from zebrafish larvae of the four
genotypes sucla2+/+, sucla2−/−, sucla2+/+;Tg(ubi:sirt5), and sucla2−/−;Tg(ubi:
sirt5) was extracted and precipitated with ethanol. MtDNA content was determined
by qPCR as above, using mt-co1 as the mitochondrial gene target and polg1 gene as
a reference for nuclear DNA content. The following primers were used: polg1-Fwd:
GAGAGCGTCTATAAGGAGTAC, polg1-Rev: GAGCTCATCA
GAAACAGGACT, mtco1-Fwd: ACTTAGCCAACCAGGAGCAC, mtco1-Rev: TC
GGGGAAATGCCATATCGG.
Oxygen consumption rate measurements. Zebrafish larvae of the four genotypes
sucla2+/+, sucla2−/−, sucla2+/+;Tg(ubi:sirt5), and sucla2−/−;Tg(ubi:sirt5) were
placed in wells of a 24-well islet microplate (one larvae in 600 μL of egg water per
well, n= 5 per group) and maintained with an islet capture screen. The plate was
loaded into an XF24 Extracellular Flux Analyzer (Seahorse Bioscience), and OCR
was measured every 5 min. Basal respiration was calculated on the average of the
last three point measurements before the injection of 2 μM FCCP to permit the
electron transport chain (ETC) to function at its maximal rate. Uncoupling
respiration was determined by the maximal value after FCCP injection. Finally,
1 μM Rotenone and 1 μg/mL Antimycin A were injected to shut down the ETC and
reveal the non-mitochondrial respiration, which was deducted from both basal and
uncoupling respiration values. Temperature was kept at 28.5 °C during the whole
experiment. Experiment was repeated three times in the exact same conditions to
ensure reproducibility and solidity.
Zebrafish survival assays. Zebrafish larvae of the four genotypes sucla2+/+,
sucla2−/−, sucla2+/+;Tg(ubi:sirt5), and sucla2−/−;Tg(ubi:sirt5), were transferred into
1.1-liter tanks and kept under constant water flow. The larvae were fed twice daily
with dry food, and dead larvae were identified and removed daily, and the genotype
was confirmed. Experiments in volume-restricted conditions were performed by
transferring zebrafish larvae into 96-well plates in a volume of 200 μL. The health of
the larvae was monitored frequently, and dead larvae or larvae with edema or
abnormal heartbeat were removed, followed by confirmation of the genotype.
Statistical analysis. All statistical analysis was performed as indicated in the main
text and figure legends. Longitudinal data of zebrafish larvae were analyzed with
Kaplan-Meier survival curves with pairwise comparison using log-rank test. p-
Value adjustment was performed by Bonferroni post-hoc test. Box-plot elements
show the following data: center line, median; box limits, upper and lower quartiles;
whiskers, 1.5x interquartile range; points, outliers.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Metabolomics data for d0 and 5 fibroblasts were deposited at Metabolomics Workbench
with the project number PR000991 [https://doi.org/10.21228/M8M116].
Raw mass spectrometry data of protein hyper-succinylation in fibroblasts and
myotubes derived from patients with mutations in succinyl-coA ligase along with
supplemental tables of identifications and quantification are available from the UCSD
proteomics resource Massive under the accession codes MSV000082599 [https://massive.
ucsd.edu/ProteoSAFe/dataset.jsp?task=7ca3028f854e4996b58f1fa1fc2286fd] and
PXD010392 [http://proteomecentral.proteomexchange.org/cgi/GetDataset?
ID=PXD010392]. The Skyline document containing the PTM spectral library and
quantitative data is available from Panorama at https://panoramaweb.org/project/
Schilling/SuccinylCoALigase/begin.view?.
Proteomics data from Rardin et al.17 used to determine changes in lysine succinylation
of TCA cycle subunits in mouse liver can be found at https://www.cell.com/cms/10.1016/
j.cmet.2013.11.013/attachment/74906873-3844-47b3-8cc5-a66cb052ecbf/mmc3.xlsx
(protein quantification) and https://www.cell.com/cms/10.1016/j.cmet.2013.11.013/
attachment/6c379a66-daf2-413f-884a-c23a478fcbae/mmc4.xlsx (peptide quantification)
The proteomics analysis from Park et al.26 on changes in lysine succinylation in
fibroblasts from control and Sirt5−/− mice can be found at https://www.cell.com/cms/
10.1016/j.molcel.2013.06.001/attachment/59f72482-fad7-48fd-a9fa-9f38fd7a9232/mmc2.xls
The homology modeling of the human SCL heterodimer is based on the structure E.
coli Succinyl-CoA synthetase with the PDB code 1CQI [https://doi.org/10.2210/
pdb1CQI/pdb].
Source data are provided with this paper. All other experimental data that support the
findings of this study are available from the corresponding authors upon reasonable
request. Source data are provided with this paper.
Code availability
R-scripts used in this study can be downloaded at https://github.com/jessegmeyerlab/
SUCLA2-deficiency.
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